Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniqu
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains
09:14am, Friday, 20'th Feb 2026
Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward e
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy?
11:05am, Wednesday, 18'th Feb 2026
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit
05:18am, Friday, 06'th Feb 2026
Tejara Capital sold 520,503 shares of Arcutis Biotherapeutics in the fourth quarter. The quarter-end position value decreased by $9.81 million, reflecting the full exit and price changes.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Thursday, 05'th Feb 2026
WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
WESTLAKE VILLAGE, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
08:00am, Monday, 26'th Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
04:00pm, Thursday, 22'nd Jan 2026
WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 ad
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
08:00am, Monday, 12'th Jan 2026
Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 million Advancement of ZORYVE indication-expansion strategy beginning with ongoing Ph
Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock
04:52am, Thursday, 08'th Jan 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT - Get Free Report) Director Howard Welgus sold 10,000 shares of the company's stock in a transaction on Friday, January 2nd. The shares were sold at an aver
Arcutis Stock Is Up 100% in a Year but Here's Why One Fund Still Sold 1 Million Shares
12:18pm, Tuesday, 23'rd Dec 2025
New York City-based Suvretta Capital Management sold nearly 1.1 million ARQT shares during the third quarter. The move contributed to a decline in the overall position value by about $35.78 million.
Zacks Industry Outlook Arcutis, Amicus and ANI
04:46am, Thursday, 18'th Dec 2025
Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
5 Biotech Stocks to Watch for Potential Upside
03:21pm, Wednesday, 17'th Dec 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
This Biotech Stock Could Cure Your Portfolio's Pain
09:15am, Sunday, 14'th Dec 2025
Arcutis already has its key drug approved for various diseases and concentrations. Sales are expanding rapidly, and Arcutis is positioned for growth.
